Loading...
Please wait, while we are loading the content...
Similar Documents
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review.
| Content Provider | Europe PMC |
|---|---|
| Author | Nardone, Valerio Romeo, Caterina D’Ippolito, Emma Pastina, Pierpaolo D’Apolito, Maria Pirtoli, Luigi Caraglia, Michele Mutti, Luciano Bianco, Giovanna Falzea, Antonella Consuelo Giannicola, Rocco Giordano, Antonio Tagliaferri, Pierosandro Vinciguerra, Claudia Desideri, Isacco Loi, Mauro Reginelli, Alfonso Cappabianca, Salvatore Tassone, Pierfrancesco Correale, Pierpaolo |
| Abstract | Non-small cell lung cancer (NSCLC) is frequently complicated by central nervous system (CNS) metastases affecting patients’ life expectancy and quality. At the present clinical trials including neurosurgery, radiotherapy (RT) and systemic treatments alone or in combination have provided controversial results. CNS involvement is even more frequent in NSCLC patients with EGFR activating mutations or ALK rearrangement suggesting a role of target therapy in the upfront treatment in place of loco-regionals treatments (i.e. RT and/or surgery). So far clinical research has not explored the potential role of accurate brain imaging (i.e. MRI instead of the routine total-body contrast CT and/or PET/CT staging) to identify patients that could benefit of local therapies. Moreover, for patients who require concomitant RT there are no clear guidelines on the timing of intervention with respect to innovative precision medicine approaches with Tyrosine Kinase Inhibitors, ALK-inhibitors and/or immuno-oncological therapies. On this basis the present review describes the therapeutic strategies integrating medical and radiation oncology in patients with metastatic NSCLC (mNSCLC) adenocarcinoma with CNS involvement and EGFR activating mutations or ALK rearrangement. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10020247&blobtype=pdf |
| ISSN | 00338362 |
| Journal | La Radiologia Medica [Radiol Med] |
| Volume Number | 128 |
| DOI | 10.1007/s11547-023-01602-z |
| PubMed Central reference number | PMC10020247 |
| Issue Number | 3 |
| PubMed reference number | 36786970 |
| e-ISSN | 18266983 |
| Language | English |
| Publisher | Springer Milan |
| Publisher Date | 2023-02-14 |
| Publisher Place | Milan |
| Access Restriction | Open |
| Rights License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2023 |
| Subject Keyword | Non-small cell lung cancer (NSCLC) Brain metastases (BM) Central nervous system (CNS) EGFR driver mutation ALK rearrangement Tyrosine kinase inhibitors (TKI) ALK inhibitors Radiotherapy |
| Content Type | Text |
| Resource Type | Article |
| Subject | Radiology, Nuclear Medicine and Imaging |
